A significant weight gain has been reported in HIV-infected patients starting combination antiretroviral therapy (cART) including integrase strand transfer inhibitors, but clinical data about changes in body fat mass are still lacking. An observational retrospective analysis was made to evaluate changes in body fat mass and weight in 39 cART-naive patients initiating a first antiretroviral treatment, including tenofovir disoproxil fumarate/emtricitabine plus raltegravir (RAL) or darunavir/ritonavir (DRV/r), and who had a follow-up of at least 12 months and a whole-body dual-energy X-ray absorptiometry performed at baseline and after 12 months. After 12 months, changes in weight and total fat mass were comparable and statistically not significant in both groups. The median increase [interquartile range (IQR)] in weight was +2.02 kg (+1.19, +2.95; p = .378) in RAL group, and +1.71 kg (+0.89, +2.54; p = .449) in DRV/r group. The median increase in body fat mass (IQR) was +1.27 kg (+1.09, +1.43; p = .278) in RAL group, and +1.04 kg (+0.89, +1.22; p = .781) in DRV/r group. In conclusion, in our study, an initial regimen including RAL plus tenofovir/emtricitabine after 12 months led to a small and nonsignificant increase in weight and body fat mass, and changes were comparable with a DRV/r-based initial regimen.

中文翻译：

---

开始使用拉特拉韦加富马酸替诺福韦二吡呋酯/恩曲他滨的未感染 HIV 的患者的体脂肪量没有显着增加。

据报道，开始接受包括整合酶链转移抑制剂在内的联合抗逆转录病毒疗法 (cART) 的 HIV 感染患者体重显着增加，但仍缺乏有关体脂肪量变化的临床数据。进行了一项观察性回顾性分析，以评估 39 名未使用 cART 的患者开始首次抗逆转录病毒治疗，包括富马酸替诺福韦二吡呋酯/恩曲他滨加雷特拉韦 (RAL) 或达芦那韦/利托那韦 (DRV/r)，以及谁进行了至少 12 个月的随访，并在基线和 12 个月后进行了全身双能 X 射线吸收测量。12 个月后，两组的体重和总脂肪量的变化具有可比性，并且在统计学上不显着。体重增加中位数 [四分位距 (IQR)] 为 +2.02 公斤（+1.19，+2.95；p  = .378) 在 RAL 组中，+1.71 kg (+0.89, +2.54; p  = .449) 在 DRV/r 组中。 RAL 组的体脂量 (IQR) 增加中位数为 +1.27 kg（+1.09，+1.43；p = .278  ），DRV/r组为 +1.04 kg（+0.89，+1.22；p = .781）组。总之，在我们的研究中，包括 RAL 加替诺福韦/恩曲他滨在内的初始方案在 12 个月后导致体重和体脂量小幅且不显着的增加，并且变化与基于 DRV/r 的初始方案相当。